Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Stock Price Down 0.6% – Here’s What Happened

Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) fell 0.6% on Thursday . The stock traded as low as $90.82 and last traded at $91.12. Approximately 21,979 shares traded hands during mid-day trading, an increase of 80% from the average session volume of 12,240 shares. The stock had previously closed at $91.69.

Invesco Biotechnology & Genome ETF Stock Performance

The stock’s fifty day simple moving average is $88.34 and its 200-day simple moving average is $83.36. The company has a market capitalization of $292.19 million, a PE ratio of 20.44 and a beta of 0.70.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

Several hedge funds and other institutional investors have recently bought and sold shares of PBE. Colonial Trust Advisors acquired a new stake in Invesco Biotechnology & Genome ETF in the 4th quarter valued at about $25,000. Fifth Third Bancorp acquired a new position in shares of Invesco Biotechnology & Genome ETF in the 1st quarter worth approximately $30,000. Comerica Bank raised its holdings in shares of Invesco Biotechnology & Genome ETF by 86.2% in the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock worth $31,000 after purchasing an additional 175 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Invesco Biotechnology & Genome ETF by 74.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock worth $40,000 after purchasing an additional 245 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of Invesco Biotechnology & Genome ETF by 63.2% in the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock worth $62,000 after purchasing an additional 342 shares in the last quarter.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.